(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-0.15%) $77.99
(0.37%) $2.15
(0.06%) $2 310.10
(0.36%) $26.79
(0.09%) $966.20
(-0.31%) $0.929
(-1.07%) $10.87
(-0.13%) $0.797
(0.35%) $91.45
3 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis...
Stats | |
---|---|
今日成交量 | 644 100 |
平均成交量 | 1.35M |
市值 | 135.87B |
EPS | ¥-2.13 ( 2024-02-13 ) |
下一个收益日期 | ( ¥35.75 ) 2024-05-08 |
Last Dividend | ¥2.50 ( 2015-03-27 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -17.42 |
ATR14 | ¥1.040 (0.07%) |
音量 相关性
Sosei Group Corporation 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Sosei Group Corporation 相关性 - 货币/商品
Sosei Group Corporation 财务报表
Annual | 2023 |
营收: | ¥12.77B |
毛利润: | ¥7.87B (61.62 %) |
EPS: | ¥-87.17 |
FY | 2023 |
营收: | ¥12.77B |
毛利润: | ¥7.87B (61.62 %) |
EPS: | ¥-87.17 |
FY | 2022 |
营收: | ¥15.57B |
毛利润: | ¥14.64B (94.05 %) |
EPS: | ¥4.67 |
FY | 2021 |
营收: | ¥17.71B |
毛利润: | ¥16.78B (94.73 %) |
EPS: | ¥12.53 |
Financial Reports:
No articles found.
Sosei Group Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
First Dividend | ¥2.50 | 2015-03-27 |
Last Dividend | ¥2.50 | 2015-03-27 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | ¥2.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9760.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8835.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8285.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7673.T | Ex Dividend Junior | 2024-05-30 | Annually | 0 | 0.00% | |
6855.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6203.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
4929.T | Ex Dividend Junior | 2024-03-18 | Annually | 0 | 0.00% | |
4099.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3315.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2384.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.563 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.0458 | 1.200 | -1.525 | -1.830 | [0 - 0.3] |
returnOnEquityTTM | -0.117 | 1.500 | -2.41 | -3.62 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.79 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.57 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.86 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.445 | -1.500 | 2.58 | -3.87 | [0 - 0.6] |
interestCoverageTTM | -3.34 | 1.000 | -2.35 | -2.35 | [3 - 30] |
operatingCashFlowPerShareTTM | -58.95 | 2.00 | -10.00 | -10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -68.47 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 1.048 | -1.500 | 5.81 | -8.71 | [0 - 2.5] |
grossProfitMarginTTM | 0.697 | 1.000 | 1.723 | 1.723 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.692 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.0753 | 1.000 | -1.530 | -1.530 | [0.2 - 2] |
assetTurnoverTTM | 0.0812 | 0.800 | -2.79 | -2.23 | [0.5 - 2] |
Total Score | -1.525 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -18.89 | 1.000 | -2.01 | 0 | [1 - 100] |
returnOnEquityTTM | -0.117 | 2.50 | -1.551 | -3.62 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -68.47 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -58.95 | 2.00 | -10.00 | -10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.160 | 1.500 | -4.40 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.413 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -4.25 |
Sosei Group Corporation
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。